Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
Date:2/4/2008

nses.

( c ) Recorded to cost of products sold.

(d) Recorded to other, net.

(e) Recorded $176 million to restructuring charges in 2007, $4 million

to selling, general and administrative expenses, $2 million to cost

of products sold, and $2 million to research and development

expenses.

(f) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item

in accordance with FASB Interpretation No. 18, "Accounting for

Income Taxes in Interim Periods.

BOSTON SCIENTIFIC CORPORATION

CONDENSED GAAP RESULTS OF OPERATIONS

(Unaudited)

Year Ended

December 31,

In millions, except per share data 2007 2006

Net sales $8,357 $7,821

Cost of products sold 2,342 2,207

Gross profit 6,015 5,614

Operating expenses

Selling, general and administrative expenses 2,909 2,675

Research and development expenses 1,091 1,008

Royalty expense 202 231

Amortization expense 641 530

Purchased research and development 85 4,119

Restructuring charges 176

Litigation-related charges 365

Loss on assets held for sale 560

6,029 8,563

Operating loss (14
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Boston Scientific to Participate in Merrill Lynch Conference
2. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
5. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
6. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
7. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
8. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
9. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
10. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
11. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... on Thursday, April 30, 2015 at 4:00 PM Eastern ... a conference call at 4:30 PM Eastern Time to ... for the future. , The conference call will be ... and in the Investor Relations section of Cytokinetics’ website ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 According ... overexertion involving an outside source was ranked first ... includes injuries related to lifting, pushing, pulling, holding, ... in direct costs. The David Round Company takes ... committed to working hard to develop and design ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Inc., (OTC ... traditional Chinese medicine (TCM) based in Chengdu,China, today ... the Board of,Directors, will host a conference call ... results., The conference call will take place ...
... 7 Dilon Technologies, makers of,a gamma imaging system ... Moussa to the position of President and Chief Executive,Officer., ... the medical device industry,having held a number of senior ... a health care corporation he ran as,CEO for a ...
... 7 MedImmune today announced,that it has strengthened ... affairs with three key promotions and has also ... Kiener, D. Phil. has been appointed,to executive vice ... organization development, HR; and Eileen Valenta to vice ...
Cached Biology Technology:Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST 2Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer' 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 3MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 4
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... for the first time a surprising and unexpected plasticity ... cells are made in early development. Scientists ... type of gene that controls cell fate by regulating ... stem and progenitor cells in blood forming tissues to ...
... (August 2, 2012) Autism Speaks, the world,s ... its expanded collaboration with Sigma Advanced Genetic Engineering ... develop the first rat models with modified autism ... autism research. Expansion of the collaboration follows ...
... in 10 children suffers from asthma but the potential ... known. Cincinnati-based researchers now report new evidence that exposure ... a direct link to asthma development during childhood. ... Penicillium variabileare typically found growing in water-damaged homes, putting ...
Cached Biology News:Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3Autism Speaks and SAGE® Labs develop rat models for translational autism research 2Autism Speaks and SAGE® Labs develop rat models for translational autism research 3Infants exposed to specific molds have higher asthma risk 2
IHC Detection Kit (Broad Spectrum AEC)....
...
...
... to L1 Cell Adhesion Molecule ... in Xq28, is involved in three distinct ... of Sylvius); 2) MASA (mental retardation, aphasia, ... (spastic paraplegia). Immunogen: ...
Biology Products: